SCHEDULE 13G/A: Deep Track Capital Discloses Significant Stake in enGene Holdings Inc.

Deep Track Capital and its affiliates have reported a beneficial ownership of 8.94% in enGene Holdings Inc., holding 4,557,575 common shares as of December 31, 2024.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, disclosing their beneficial ownership in enGene Holdings Inc.
• As of December 31, 2024, the reporting persons collectively beneficially own 4,557,575 common shares of enGene Holdings Inc.
• This ownership represents 8.94% of the total outstanding common shares of enGene Holdings Inc.
• The calculation of the percentage of class is based on 50,976,676 common shares outstanding as of December 16, 2024, as reported in the issuer's 10-K filing on December 19, 2024.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing beneficial ownership, which is inherently neutral in sentiment. It provides factual information about an investor's stake without discussing company performance or future prospects.

Positives

• A significant institutional investor, Deep Track Capital, has taken a substantial stake in enGene Holdings Inc., potentially signaling confidence in the company's prospects.

Future Outlook

NA

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

The investment by Deep Track Capital, a firm specializing in biotechnology, suggests continued investor interest in the biotechnology sector, particularly in companies like enGene Holdings Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Deep Track Capital may influence investor perception and potentially the stock's trading activity, signaling institutional confidence.

Key Dates

Keywords

enGene Holdings Inc., Deep Track Capital, beneficial ownership, Schedule 13G, common shares, institutional investment, biotechnology